Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 3, 2003, Pages 242-252

  Démolis, Jean Louis ^b   Vacheron, Françoise ^b   Cardus, Stéphane ^b   Funck Brentano, Christian ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; TELITHROMYCIN;

ABDOMINAL PAIN; ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ELECTROCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEADACHE; HEART RATE; HUMAN; MALE; MEASUREMENT; NAUSEA; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; REST; RR INTERVAL; TASTE DISORDER; VERTIGO;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; KETOLIDES; MACROLIDES; MALE; REFERENCE VALUES; REST;

EID: 0037374044     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2003.4     Document Type: Article

References (32)

1. Balfour JA, Figgitt DP. Telithromycin. Drugs 2001;61:815-29.
2. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000;47:219-33.
3. Singh BN. When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol 1989;63:867-9.
4. Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med 1994;331:785-91.
5. Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol 1997;80:82G-89G.
6. Yap YG, Camm J. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause QT prolongation. BMJ 2000;320:1158-9.
7. Aventis Pharma. Ketek (telithromycin) briefing document for the FDA Anti-infective Drug Products Advisory Committee Meeting. March 2001. Available at http://www.fda.gov/ohrms/dockets/ac/01/briefing/3746b_01_aventis.pdf. Accessed Jan 17, 2003.
8. Tschida SJ, Guay DR, Straka RJ, Hoey LL, Johanning R, Vance-Bryan K. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature. Pharmacotherapy 1996;16:663-74.
9. Daleau P, Lessard E, Groleau MF, Turgeon J. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 1995;91:3010-6.
10. Stramba-Badiale M, Nador F, Porta N, Guffanti S, Frediani M, Colnaghi C, et al. QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Am Heart J 1997;133:108-11.
11. Lee KL, Jim MH, Tang SC, Tai YT. QT prolongation and torsades de pointes associated with clarithromycin. Am J Med 1998;104:395-6.
12. Namour F, Wessels DH, Pascual MH, Reynolds D, Sultan E, Lenfant B. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother 2001;45:170-5.
13. Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993;25:189-204.
14. Demolis JL, Martel C, Funck-Brentano C, Sachse A, Weimann HJ, Jaillon P. Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. Br J Clin Pharmacol 1997;44:403-9.
15. Demolis JL, Charransol A, Funck-Brentano C, Jaillon P. Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers. Br J Clin Pharmacol 1996;41:499-503.
16. Demolis JL, Kubitza D, Tenneze L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000;68:658-66.
17. Funck-Brentano C, Kibleur Y, Lecoz F, Poirier JM, Mallet A, Jaillon P. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans. Circulation 1991;83:536-45.
18. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;70:353-70.
19. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol 1993;72:17B-22B.
20. Fridericia LS. Die Sytoledauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand 1920;53:522-34.
21. Sarma JS, Sarma RJ, Bilitch M, Katz D, Song SL. An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: reevaluation of Bazett's formula. Am J Cardiol 1984;54:103-8.
22. Committee for Proprietary Medicinal Products. Point to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products; 1997. Available at http://www.emea.eu.int/pdfs/human/swp/098696en.pdf. Accessed Jan 17, 2003.
23. van Haarst AD, van't Klooster GA, van Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998;64:542-6.
24. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999;65:10-20.
25. Flockhart DA, Drici MD, Kerbusch T, Soukhova N, Richard E, Pearle PL, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000;20:317-24.
26. Adamantidis MM, Caron JF, Dumotier BM, Bordet RC. Clarithromycin lengthens action potential duration in rabbit Purkinje fibers: relationship with clinical case reports of QT prolongation and torsade de pointes [abstract]. Fundam Clin Pharmacol 1999;13:343.
27. Kamochi H, Nii T, Eguchi K, Mori T, Yamamoto A, Shimoda K, et al. Clarithromycin associated with torsades de pointes. Jpn Circ J 1999;63:421-2.
28. Hayashi Y, Ikeda U, Hashimoto T, Watanabe T, Mitsuhashi T, Shimada K. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin Electrophysiol 1999;22:672-4.
29. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab Dispos 1997;25:623-30.
30. Tinel M, Descatoire V, Larrey D, Loeper J, Labbe G, Letteron P, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989;250:746-51.
31. Spicer ST, Liddle C, Chapman JR, Barclay P, Nankivell BJ, Thomas P, et al. The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol 1997;43:194-6.
32. Labbe G, Flor M, Lenfant B. HMR3647, a new ketolide antimicrobial, does not inhibit cytochrome P450 activity in vitro [abstract]. J Antimicrob Chemother 1999;44(Suppl A):61.